Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC) No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback